Study Site Locations

Please contact the site closest to you for study inquiries or to discuss a patient referral.

Search within
Miles of

AZ

Retinal Consultants of Arizona/ Retinal Reseach Institute

Neal Palejwala

15401 N. 29th Ave.

Phoenix

, 

AZ

, 85053

Rebekah Bratton

602-977-6154

AR

Retina Partners of Northwest Arkansas

Serrhel Adams

601 West Maple Avenue Suite 205A

Springdale

, 

AR

, 72764

Ethan Korpella

CA

Bay Area Retina Associates

Roger Goldberg

365 Lennon Ln. Suite 250 & 270

Walnut Creek

, 

CA

, 94598

Ana Magsayo

CA

Macula and Retina Institute

Kent Small

411 N Central Ave Ste 115

Glendale

, 

CA

, 91203

Amber Diaz

CO

Eye Center of Northern Colorado

Brittney Statler

3151 Precision Dr

Fort Collins

, 

CO

, 80528

Andrea Lopez

CO

RSC Research, PLLC

Ross Chod

950 E. Harvard Ave Suite 530

Denver

, 

CO

, 80210

Ronald Farmer

CT

Connecticut Eye Consultants, P.C.

Richard Scartozzi

69 Sand Pit Road Suite 101

Danbury

, 

CT

, 06810

Mackenzee George

FL

Eye Associates of Pinellas

Jason Handza

9375 66th St N

Pinellas Park

, 

FL

, 33782

Mariah Kilgore

FL

Retina Specialists of Tampa

Evan Dunn

2400 Cypress Glen Drive

Wesley Chapel

, 

FL

, 33544

Tracy Warner

FL

Retina Specialty Institute

Sunil Gupta

5150 N Davis Hwy

Pensacola

, 

FL

, 32503

Sarah Faruzzi

FL

Retina Vitreous Associates of Florida

Ashley Crane

12903 N 56th

Tampa

, 

FL

, 33617

Ledra Bataku

MA

Ophthalmic Consultants of Boston

Chirag Shah

50 Staniford St Ste 600

Boston

, 

MA

, 02114

Maria Jose Martinez Lopez

VA

The Retina Group of Washington

Alexander Melamud

8270 Willow Oaks Corporate Drive Suite 600

Fairfax

, 

VA

, 22031

Rachel Rivera

MD

The Retina Care Center

Eric Suan

6115 Falls Road Suite 300

Baltimore

, 

MD

, 21209

Amanda McGee

MI

Foundation for Vision Research

Thomas Aaberg

5030 Cascade Rd. SE

Grand Rapids

, 

MI

, 49546

Eric Hederstedt

MI

Vitreoretinal Specialist, PLC.; DBA- Retina Associates of Michigan

Raafay Sophie

8562 Holly Rd.

Grand Blanc

, 

MI

, 48439

Tracy Utley

MS

Deep Blue Retina Clinical Research PLLC

Jorge Calzada

7900 Airways Boulevard Building A, Suite 1

Southaven

, 

MS

, 38671

Jen Cooper

NJ

NJ RETINA

Paul Hahn

628 Cedar Lane

Teaneck

, 

NJ

, 07666

Emily Diaz Osorio

NJ

NJ Retina

Daniel Roth

530 Lakehurst Rd Suite 305

Toms River

, 

NJ

, 08755

Dina Christodoro

OK

Tulsa Retina Consultant

Joaquin Tosi

2424 E. 21st Street Suite 200

Tulsa

, 

OK

, 74114

Kim Sargent

OR

Verum Research LLC

Albert Edwards

1011 Valley River Way Suite 110

Eugene

, 

OR

, 97401

Lillian Carroll

TX

San Antonio Eye Center

Gawain Dyer

511 Dallas St.

San Antonio

, 

TX

, 78215

Tyler Kostopoulos

UT

Retina Associates of Utah

Robert Kwun

5169 S Cottonwood St Suite 630

Salt Lake City

, 

UT

, 84107

Brittany Brewster

UT

Rocky Mountain Retina Consultants

Mitchel Goff

4400 South 700 East Suite #200

Salt Lake City

, 

UT

, 84107

Donna Knight

UT

Salt Lake Retina

Andrew Davis

3855 W. 7800 South Suite #100

West Jordan

, 

UT

, 84088

Tamara Sailors

VA

Piedmont Eye Center

Golnaz Javey

116 Nationwide Drive

Lynchburg

, 

VA

, 24502

Susan Shelton

VA

Retina Associates, PC

Andrew McFarland

1901 Campus Blvd Suite 320

Winchester

, 

VA

, 22601

Kaitlyn Poppo

MD

Retina Group of Washington

Michael Lai

5454 Wisconsin Ave Suite 650

Chevy Chase

, 

MD

, 20815

Danielle Downer

eye charteye chart

Inclusion and Exclusion Criteria

Patients who meet the following criteria may be eligible to participate: Inclusion • Male or female subjects, ≥50 years of age. • Documented diagnosis of wAMD in the study eye, with onset of disease that began at any time prior to the Screening Visit. • Active subfoveal CNV due to wAMD, including juxtafoveal lesions that affect the fovea, as defined by presence of fluid (intraretinal or subretinal) affecting the central subfield as measured by SD-OCT. Exclusion • CNV caused by ocular histoplasmosis, pathological myopia, angioid streaks, choroidal rupture, uveitis, and trauma. • Fibrosis >50% of the total lesion. This is not a full list of criteria.

FAQ’s

What is the primary objective of the EYP-1901-301 study?

To evaluate the efficacy of EYP-1901 intravitreal (IVT) insert on best corrected visual acuity (BCVA) changes compared to aflibercept treatment.

What is the study drug being evaluated in the EYP-1901-301 study?

EYP-1901 (vorolanib intravitreal [IVT] insert)

If my patient qualifies for the EYP-1901-301 study, will they receive the study drug?

Participants will be randomly assigned to one of two treatment groups: EYP-1901 or aflibercept.

How many participants will be in this study?

Approximately 400 participants will be enrolled.